Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Allergan, Inc.
United Health's pharmacy benefit manager outlined plans for early inclusion of up to three biosimilar versions of adalimumab on its formularies in 2023, at parity to the brand.
Shortage began in August and has increased the onset of cough/cold season due to consumers’ “stockpiling/panic buying” in response to high levels of activity in COVID-19, RSV, seasonal flu and other viruses, according to Canadian Pharmacists Association. Health Canada has approved imports of Haleon and J&J children’s pain relievers.
Sun Pharmaceuticals continues to dominate the Indian pharmaceutical space while its R&D costs are set to rise.
VC Investment in South Korea’s biopharma sector drops again as investors continue to shy away amid higher interest rates and reduced out-licensing deals.
- OTC, Consumer
- Specialty Pharmaceuticals
- Controlled Release
- Site Specific
- Implantable Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- MAP Pharmaceuticals, Inc. (MAPP)
- Oculex Pharmaceuticals, Inc.
- SkinMedica, Inc.